Drug Approval | September 28, 2024
FDA approves Bristol Myers Squibb’s Cobenfy
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
The Shasta system and Shasta Whole-Genome Amplification (WGA) Kit dramatically increase throughput for WGA by processing up to 1,500 cells per run
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
This license will enable Abbott to enhance access to this novel therapy to more patients across India
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
ALS patients experience neuroinflammation and rapid neurodegeneration
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
